$36.90
1.54% today
Nasdaq, Feb 28, 04:48 pm CET
ISIN
US74366E1029
Symbol
PTGX

Protagonist Therapeutics, Inc. Stock price

$36.34
-2.02 5.27% 1M
-5.92 14.01% 6M
-2.26 5.85% YTD
+6.75 22.81% 1Y
+12.06 49.67% 3Y
+28.52 364.71% 5Y
+24.64 210.60% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+0.19 0.53%
ISIN
US74366E1029
Symbol
PTGX
Sector
Industry

Key metrics

Market capitalization $2.23b
Enterprise Value $1.82b
P/E (TTM) P/E ratio 8.64
EV/FCF (TTM) EV/FCF 9.97
EV/Sales (TTM) EV/Sales 4.20
P/S ratio (TTM) P/S ratio 5.13
P/B ratio (TTM) P/B ratio 3.28
Revenue growth (TTM) Revenue growth 624.06%
Revenue (TTM) Revenue $434.43m
EBIT (operating result TTM) EBIT $252.84m
Free Cash Flow (TTM) Free Cash Flow $182.80m
Cash position $418.91m
EPS (TTM) EPS $4.21
P/E forward negative
P/S forward 25.64
EV/Sales forward 20.95
Short interest 6.45%
Show more

Is Protagonist Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Protagonist Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Protagonist Therapeutics, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Protagonist Therapeutics, Inc. forecast:

Buy
91%
Hold
9%

Financial data from Protagonist Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
434 434
624% 624%
100%
- Direct Costs 2.96 2.96
11% 11%
1%
431 431
661% 661%
99%
- Selling and Administrative Expenses 38 38
40% 40%
9%
- Research and Development Expense 138 138
15% 15%
32%
256 256
383% 383%
59%
- Depreciation and Amortization 2.96 2.96
11% 11%
1%
EBIT (Operating Income) EBIT 253 253
370% 370%
58%
Net Profit 275 275
449% 449%
63%

In millions USD.

Don't miss a Thing! We will send you all news about Protagonist Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Protagonist Therapeutics, Inc. Stock News

Neutral
Accesswire
7 days ago
$165.0 million icotrokinra (formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025 PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide nominated as a development candidate in Q4 2024 Topline results for rusfertide Phase 3 VERIFY clinical trial in polycythemia vera expected in March 2025 Topline results for icotrokinra Phase 2b ANTHEM clinical trial in mode...
Positive
Seeking Alpha
about 2 months ago
Positive results achieved from both ICONIC studies using JNJ-2113 for the treatment of patients with moderate-to-severe plaque psoriasis; Superiority study is data expected in Q2 of 2025. Topline results from the phase 3 VERIFY study, using rusfertide for the treatment of patients with polycythemia vera, expected in Q1 of 2025. The global Polycythemia vera market size is expected to grow to $2....
Neutral
Accesswire
about 2 months ago
NEWARK, CALIFORNIA / ACCESSWIRE / January 6, 2025 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his appointment to the role of Executive Vice President, Chief Scientific Officer, in accordance with the terms of his employment offer letter.
More Protagonist Therapeutics, Inc. News

Company Profile

Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Head office United States
CEO Dinesh Patel
Employees 126
Founded 2006
Website www.protagonist-inc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today